Synairgen (GB:SNG) has released an update.
Synairgen plc has announced its preliminary financial results for 2023, highlighting a strategic focus on developing SNG001, a potential antiviral treatment for severe viral lung infections, with an upcoming Phase 2 trial targeted at mechanically ventilated patients. The company has reported a reduced operational loss and a strong cash position, indicating prudent cost control measures. Moreover, Synairgen continues to collaborate on the UNIVERSAL trial and remains open to future partnerships.
For further insights into GB:SNG stock, check out TipRanks’ Stock Analysis page.
